Dr. Baselga Discusses PIK3CA Inhibitors in Breast Cancer

José Baselga, MD, PhD, Physician-in-Chief, Memorial Sloan-Kettering Cancer Center, discusses treatment with PIK3CA inhibitors in patients with breast cancer.

Baselga says that PIK3CA inhibitors are very selective for cell lines that harbor the alpha mutation. Patients can often handle a higher dosage of this class of inhibitors as there is a different side effect profile, marking a potential advantage.

This subtype is sensitive to targeted agents, which allows for the blocking of the PIK3CA subunit very specifically.